Promise and failure of targeted therapy in breast cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Breast cancer (BC) molecular targets were identified pre-genomic era, with relevance validated by gene profiling.
• Five BC subtypes (luminal A, luminal B, normal-like, HER2-positive, basal) defined by gene signatures.
• Subtypes differ in receptor status: Luminal A/B are estrogen receptor (ER)-positive; basal-like are triple-negative; HER2-positive overexpresses HER2.

Purpose of the Study:

• To summarize current targeted therapeutic options for luminal, HER2-positive, and basal-like BC subtypes.
• To evaluate treatment efficacy based on clinical trial results for optimizing application in various clinical settings.
• To provide insights into ER- and HER2-targeted therapies and promising options for basal-like BC.

Main Methods:

• Review of current targeted therapeutic options for defined BC subtypes.
• Analysis of clinical trial data for luminal, HER2-positive, and basal-like BC.
• Consideration of approved ER- and HER2-targeted therapies and emerging basal-like treatments.

Main Results:

• Summary of targeted therapies for luminal, HER2-positive, and basal-like BC subtypes based on clinical trial outcomes.
• Evaluation of merits and shortcomings of ER- and HER2-targeted therapies in early and advanced disease.
• Identification of currently available and promising therapeutic options for basal-like BC.

Conclusions:

• Optimizing targeted therapy application in BC requires understanding subtype-specific responses.
• ER- and HER2-targeted therapies show variable efficacy in early vs. advanced disease.
• Further research into basal-like BC therapies is crucial for improved patient outcomes.